Utilizing Protein Structure to Identify Non-Random Somatic Mutations by Ryslik, Gregory et al.
ar
X
iv
:1
30
2.
69
77
v1
  [
q-
bio
.G
N]
  2
7 F
eb
 20
13
Utilizing Protein Structure to Identify
Non-Random Somatic Mutations
Gregory Ryslik1, Yuwei Cheng2, Kei-Hoi Cheung2,3, Yorgo Modis4,
and Hongyu Zhao1
1Department of Biostatistics, Yale School of Public Health, New
Haven, CT, USA
2Program of Computational Biology and Bioinformatics, Yale
University, New Haven, CT, USA
3Yale Center for Medical Informatics, Yale School of Medicine,
New Haven, CT, USA
4Department of Molecular Biophysics & Biochemistry, Yale
University, New Haven, CT,USA
October 17, 2018
Abstract
Motivation: Human cancer is caused by the accumulation of somatic
mutations in tumor suppressors and oncogenes within the genome. In the
case of oncogenes, recent theory suggests that there are only a few key
“driver” mutations responsible for tumorigenesis. As there have been sig-
nificant pharmacological successes in developing drugs that treat cancers
that carry these driver mutations, several methods that rely on mutational
clustering have been developed to identify them. However, these methods
consider proteins as a single strand without taking their spatial structures
into account. We propose a new methodology that incorporates protein
tertiary structure in order to increase our power when identifying muta-
tion clustering.
Results: We have developed a novel algorithm, iPAC (identification of
Protein Amino acid Clustering), for the identification of non-random so-
matic mutations in proteins that takes into account the three dimensional
protein structure. By using the tertiary information, we are able to de-
tect both novel clusters in proteins that are known to exhibit mutation
clustering as well as identify clusters in proteins without evidence of clus-
tering based on existing methods. For example, by combining the data in
the Protein Data Bank (PDB) and the Catalogue of Somatic Mutations
in Cancer, our algorithm identifies new mutational clusters in well known
cancer proteins such as KRAS and PI3KCα. Further, by utilizing the ter-
tiary structure, our algorithm also identifies clusters in EGFR, EIF2AK2,
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and other proteins that are not identified by current methodology.
Availability: R package available on Bioconductor at
http://www.bioconductor.org/packages/2.12/bioc/html/iPAC.html.
Contacts: gregory.ryslik@yale.edu; hongyu.zhao@yale.edu
1 Introduction
Cancer is one of the most widespread and heterogeneous diseases imposing
a huge toll on patients, relatives, friends, and society. However, at its most
basic, it is a genetic disease that is caused by the accumulation of somatic
mutations in oncogenes and tumor suppressors (Vogelstein and Kinzler, 2004).
While mutations in tumor suppressors tend to down-regulate the activity of
genes that prevent cancer, mutations in proto-oncongenes either up-regulate
or deregulate the activities of the resulting proteins. So far, pharmacological
intervention has shown to be more successful inhibiting the activating onco-
genes than restoring tumor suppressing gene function. Coupled with the idea
of “oncogene addiction”, that many cancers rely on mutations in a small sub-
set of key genes to be able to continue their uncontrolled growth while the
remainder of the mutations constitute passenger mutations (Greenman et al.,
2007; Weinstein and Joe, 2006), the problem of identifying activating oncogenic
mutations has received great attention in cancer research.
Recently, several studies have shown support for the hypothesis that activat-
ing somatic mutations tend to cluster in protein kinases (Torkamani and Schork,
2008; Greenman et al., 2007; Bardelli et al., 2003). Further, as observed by
Ye et al. (2010), mutational clusters might provide further information regard-
ing where to look for activating mutations, reducing the driver mutation search
space needed to be analyzed. Moreover, mutational clusters that lead to ei-
ther beneficial or detrimental phenotypic changes may point to regions that are
under positive or directional selection as well as regions that are functionally
significant and thus can be targeted by protein engineering (Wagner, 2007).
So far, several methods based upon the number of mutations in a specific re-
gion have been developed to detect potential driver oncogenic mutations as well
as naturally selected regions. One common method hypothesizes that driver
mutations have a higher non-synonymous mutation rate as compared to the
background mutation rate (Sjblom et al., 2006; Bardelli et al., 2003). Further,
one can look at the ratio of nonsynonymous (Ka) to synonymous (Ks) changes
per site, Ka
Ks
(Kreitman, 2000). A criterion for selection is then to check if
Ka
Ks
> 1, based on the hypothesis that the benchmark neutral rate of nucleotide
substitution is exceeded when positive selection also contributes to the sub-
stitution process. Similarly, Wang (2002) proposes a hypothesis that driver
mutations have a larger mutational rate than the background mutational rate
after gene length normalization.
While the approaches mentioned above have had some success in detecting
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positive selection and/or identifying driver mutations, they nevertheless have
several shortcomings. First, many of them are dependent on calculating the
disparity in non-synonymous versus synonymous mutations but do not recognize
that selection often occurs on very small sections of the gene and thus might
fail when averaged over the entirety of the gene length. Second, the methods
described above (Wang, 2002; Kreitman, 2000) do not make any attempt to
distinguish between activating and non-activating non-synonymous mutations.
In addition to the approaches described above, some researchers have fo-
cused on creating classifiers in order to determine mutation status. As described
in Reva et al. (2011), these algorithms employ a variety of machine learning
techniques, such as Random Forests (Breiman, 2001) and Support Vector Ma-
chines (Cortes and Vapnik, 1995), to calculate a score for each mutation. These
scores are typically calculated using a combination of physico-chemical prop-
erties such as evolutionary conservation, size and polarity of substituted and
original residues as well as surface accessibility. These scores are then used to
classify the mutation. For example, PolyPhen-2 (Adzhubei et al., 2010) pre-
dicts whether a missense mutation is damaging while CHASM (Carter et al.,
2009) attempts to discriminate between driver and passenger mutations. While
several of these models have had significant success in classifying the mutation,
they all require large and well annotated data sets in order to first train the
machine learning classifier and then apply the resulting rule set.
Recently, Ye et al. (2010) developed Non-Random Mutational Clustering
(NMC) to identify potential activating mutations by hypothesizing that, in
the absence of heretofore known mutational hotspots, a mutational cluster is
indicative of selection for an activating driver mutation since only a small num-
ber of precise mutations can activate a protein (Torkamani and Schork, 2008;
Bardelli et al., 2003). By looking at the order statistics and assuming that the
locations of amino acid mutations follow a uniform distribution when the protein
is considered in linear form under the null hypothesis, they identify clusters by
calculating whether any two pair-wise mutations are closer together on the line
than expected by chance alone. Despite its success, one limitation of the NMC
method is that the proteins are treated as a linear sequence without considering
the three dimensional structures of the proteins.
In this work, we extend the NMC methodology to account for tertiary pro-
tein structure. This enables the identification of mutational clusters that are
relatively far away in linear space but relatively close together in 3D space. We
proceed to show that our methodology is effective in identifying novel muta-
tional clusters that are missed by NMC in key cancer proteins such as KRAS and
PIK3Cα. Unlike NMC, iPAC is also able to identify the EGFR and EIF2AK2
proteins as containing mutational clustering as well. We also show that many of
the clusters identified by iPAC are predicted to be deleterious by well known ma-
chine learning algorithms such as Polyphen-2 (Adzhubei et al., 2010). However,
iPAC has the distinct advantage of requiring only the mutational positions and
tertiary structure which allows its application to novel mutations and structures
for which extensive information and literature is not yet available. Finally, we
also show that for a large percentage of protein structures, the tertiary struc-
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ture leads to a net reduction in mutational clusters found, thus presenting a
simplified clustering mutational landscape. Ultimately, by providing a refined
picture of the mutational clustering, we are are able to provide a more accurate
representation of where potential activating mutations may reside within the
protein.
2 Methods
Our method, named iPAC , uses a 4 step approach to finding mutational clus-
ters. First, mutational and positional data are obtained from the COSMIC
(Forbes et al., 2008) and PDB (Berman et al., 2000) databases (described in
Sections 2.1 and 2.2, respectively). The mutational and positional information
is then reconciled to allow a single numerical reference to identify the same
physical amino acid in both databases (Section 2.3). Next, MultiDimensional
Scaling (MDS) (Borg and Groenen, 1997) is used to map the protein structure
from 3D to 1D space while preserving, as best as possible, all pairwise three di-
mensional distances between amino acids for a given protein (Section 2.4). The
NMC algorithm is then run on the remapped amino acids to find mutational
clusters (Section 2.5). Finally, the clusters are mapped back into the original
protein space and reported back to the user. In the following subsections we
discuss each of these steps in detail.
2.1 Obtaining Mutational Data
Mutational data were obtained from the COSMIC database (version 58) via
ftp://ftp.sanger.ac.uk/pub/CGP/cosmic and implemented using Oracle. In
order to justify the assumption that amino acids follow a uniform distribu-
tion of mutation, only mutations that were found through whole gene screens
were included. Further, we only used missense mutations that belonged to two
categories: 1) “Confirmed somatic variant” or 2) “Reported in another cancer
sample as somatic”. All nonsense and synonymous mutations as well as mu-
tations that had different somatic status categories were excluded. Further, as
multiple studies can report mutational data from the same cell line, mutational
redundancies were removed to avoid double counting. See “COSMIC query” in
the supplementary information for the SQL code and schema used to generate
the data. Finally, in order to match mutational data with structural data, only
the proteins for which a UniProt Accession Number (Consortium, 2011) was
available were kept. This resulted in 777 unique proteins.
2.2 Obtaining the 3D Structural Data
The protein structural data were obtained from the PDB database via http://www.pdb.org.
As one protein can have several structures, for each of the 777 proteins described
above, all the structures with a matching UniProt Accession Number were ob-
tained. If a specific structure had more than one polypeptide chain with a
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matching amino acid sequence in UniProt, the first matching chain listed was
used (typically chain A). For proteins where the resolution was sufficiently high
enough to provide more than one alternative conformation for a specific amino
acid side chain, only the first conformation listed in the file was used. Once the
appropriate side chain and conformation was selected, the (x, y, z) coordinates
of all the α-carbon atoms were extracted and used to represent the 3D back-
bone structure of the protein. In all, this process resulted in 1,904 structures.
See “Structure Files” in the supplementary information for a full listing of the
structures and side chains used for each protein considered.
2.3 Reconciling the Structural and Mutational Data
Due to a different numbering system of the amino acids employed by the PDB
and COSMIC databases, an alignment needed to be performed in order to refer-
ence the same residue numerically in both databases. Two methods in the iPAC
package were designed to reconcile these differences, one based on pairwise align-
ment (Pages et al., 2012) and the other based on a numerical reconstruction
from the structural data obtained from the PDB. As there are often significant
technical difficulties for such a reconstruction, for the rest of this paper, un-
less specifically noted, pairwise alignment was used to reconcile these elements.
Please see the documentation in the iPAC package for a full description of these
two methods. Successful alignment of mutational and positional data occurred
on 140 proteins which corresponded to 1100 unique structure/side-chain combi-
nations and 667 unique residue positions containing 1,434 total mutations. We
note that for any given structure/side-chain combination, if there is no posi-
tional data for a specific residue, the mutational data for that residue is not
used. Please see “Structure Files” in the supplementary information for a full
description.
2.4 Multidimensional Scaling
As the underlying clustering algorithm is dependent upon the construction of or-
der statistics, we used MDS (Borg and Groenen, 1997) to remap the amino acids
into one dimensional space while preserving (as best as possible) the pairwise
distances between them in 3D space. Specifically, given an n × n dissimilarity
matrix,
∆n,n =


δ1,1 δ1,2 · · · δ1,n
δ2,1 δ2,2 · · · δ2,n
...
...
. . .
...
δn,1 δn,2 · · · δn,n


the MDS algorithm maps each δi,j into a corresponding distance di,j(X) on a
new m-dimensional metric spaceX. Formally, for a specific representation func-
tion, f : δi,j → di,j(X), we have that the original dissimilarities are preserved in
X, specifically, f(δi,j) = di,j(X). Here, f can be either fully defined or chosen
from a specified class of functions and is employed to handle the case when
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the proximity measures come from a space that is not necessarily a true metric
space. Further, as it is not always possible to preserve the exact distance (for
example, due to sampling effects, measurement precision or loss of dimensional-
ity), rather than insist on f(δi,j) = di,j(X), the MDS framework is typically set
up such that f(δi,j) ≈ di,j(X). Thus, by minimizing a badness-of-fit measure
called raw stress = σr =
∑
i,j [f(δi,j)− di,j(x)]
2, we identify the x1, ...,xn, that
preserve our distances in the new metric space X. However, raw Stress by itself
is not always informative as it is subject to distortion by the choice of units
used. For instance, if the scale used to measure changes by a factor of 100, the
raw stress will change as well but by a factor of 1002. Thus, Stress-1, which is
defined as:
σ1 =
√∑
i,j [f(δi,j)− di,j(X)]
2∑
i,j d
2
i,j(X)
(1)
and is not subject to unit distortion, will be minimized instead.
For the purposes of this paper, the dissimilarity matrix is simply equal to
pair-wise distance between any two amino acids in the protein. Specifically, the
distance between residues i and j, denoted δi,j , is taken to be the Euclidean
distance between their respective α-carbon atoms. As Euclidean space is a
proper metric space, from now on we assume that f is the identity function.
Further, as we require units along the line in order to calculate order statistics,
the MDS algorithm will be applied such that we find x1, ...,xn ∈ R
1. Thus, the
MDS algorithm finds scalars x1, ..., xn such that |xi − xj | ≈ δi,j , for any two
pairwise amino acids i and j in the protein. We present an example when MDS
is applied to the 3GFT structure of KRAS (Tong et al., 2009) in Figures 1 and
2 below.
2.5 NMC
We employed the NMC algorithm (Ye et al., 2010) to find the mutational clus-
ters in one dimensional space. Specifically, consider a protein with N amino
acids and that each amino acid has a uniform probability of 1
N
of mutation.
Given m samples and n mutations, we are able to calculate the order statistics
for every mutation (see Figure 3). Two mutations X(i) and X(k) are then de-
fined to be clustered if, Pr(Cki = X(k) − X(i)) ≤ α. This probability is then
calculated for every pair of mutations and adjusted for multiple comparisons us-
ing either the Benjamini-Hochberg (BH) adjustment (Benjamini and Hochberg,
1995) or the Bonferroni adjustment. For the analyses performed in this paper,
the more conservative Bonferroni adjustment was used. Finally, it is important
to note that the structural information obtained for each protein often does
not include positional information on every amino acid within the protein. We
removed these “missing” amino acids from the protein before running the NMC
clustering algorithm so that we can compare iPAC and NMC on an equal basis.
Ye et al. (2010) derive closed form solutions to calculate the Pr(Cki = c) for
c ∈ {0, 1, ..., N − 1}. However, as this becomes computationally inefficient, they
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Figure 1: KRAS α-carbons in 3D Space.
Figure 2: KRAS α-carbons mapped to
the x-axis using MDS.
Figure 3: An example of constructing the order statistics. Suppose we had 3 samples of a
protein that is N amino acids long. If amino acid i has a “*” above it, that indicates that the
amino acid for that sample had a non-synonymous missense mutation. The samples are then
collapsed together and the number of mutations for each residue is shown above the box on the
right. These counts form the order statistics. The first mutation is on residue 2 (X(1) = 2),
the next 3 mutations are on residue 3 (X(2) = X(3) = X(4) = 3) , the next mutation is on
residue 5 (X(5) = 5) and the last 2 mutations are on residue 6 (X(6) = X(7) = 6).
suggest dividing Cki by N and assuming a continuous uniform distribution on
(0, 1). They then show that in the limit, the CDF becomes as follows:
Pr(
Cki
N
=
X(k) −X(i)
N
≤ c)
=
∫ c
0
n!
(k − i− 1)!(i+ n− k)!
yk−i−1(1 − y)i+n−kdy
= Pr(Beta(k − i, i+ n− k + 1) ≤ c)
(2)
Thus, via Equation (2), we can directly calculate if two mutations are closer
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together than by chance quickly and efficiently.
2.6 Multiple Comparison Adjustment For Structures
In addition to the Bonferroni multiple comparison adjustment done by the NMC
method, an adjustment is also required to account for testing multiple structures
per protein. Since the structures for a given protein could be quite similar and
thus lead to similar clustering results, a second Bonferroni adjustment would
be too conservative. Instead, a combined Bonferroni-FDR approach was per-
formed as follows. First, for a given protein, the NMC reported p-value for a
given cluster was multiplied by n(n−1)2 , to calculate P
∗. Thus, on a per-protein
level, P ∗ represents the inverse Bonferroni adjustment performed by the NMC
algorithm and thus allowed us to compare each cluster’s P ∗ to an α-level of
0.05 to determine significance. To account for all the structures analyzed, we
computed a rough FDR (rFDR) (Gong et al., 2009):
rFDR = α ∗
k + 1
2k
where k is the total number of structures. In the case of the 1100 struc-
tures analyzed in this study, rFDR ≈ 0.02502. Finally, any clusters for which
P∗ ≤ 0.02502 was deemed to be significant. For the rest of this paper, with the
exception of Table 1, we only report the p-value to avoid confusion. Neverthe-
less, each cluster presented in Section 3 is in fact significant after adjusting for
structural multiple comparisons.
3 Results
Using the iPAC package, 215 of the total 1100 structures analyzed were found
to have significant clustering. When comparing iPAC with the original NMC
method, out of the 140 proteins analyzed, both iPAC and NMC identified 8
proteins that contained significant clusters. However, iPAC also identified 3 new
proteins as well, specifically EGFR, EIF2AK2 and HAO1. These 3 new proteins
correspond to 10 of the 215 structures found to have clustering. iPAC also found
structure 2ENQ for the protein PIK3CA to contain a significant cluster while
NMC did not. The 8 proteins identified by both algorithms correspond to the
remaining 204 structures. There were no proteins that were identified by NMC
but were subsequently missed by the iPAC algorithm. Please see “Results
Summary” in the supplementary materials for a full listing of which structures
and which proteins were found to be significant.
As can be seen from Figure 4, approximately 70% of all the structures found
to have significant clustering differed in the amount of clusters identified when
comparing iPAC vs NMC. This leads one to believe that in some cases, con-
sideration of the tertiary structure identifies additional clusters while in other
cases, clusters are able to be removed, offering a simplified view of the muta-
tional information. While it is outside the scope of this paper to consider every
8
Figure 4: A comparison of NMC and iPAC over all the structures that were found to be
significant.
one of the 215 structures with clustering, we present three representative cases
where integration of the tertiary protein structure into the analysis had a sig-
nificant effect: 1) identification of mutation clustering in a protein that would
otherwise be missed, 2) identification of new mutation clusters in a protein that
was detected using the NMC methodology, and 3) reduction of the total muta-
tional clusters in a protein that was detected using the NMC methodology. We
also note, as can be seen in Table 1, that the p-value found for the most signif-
icant cluster is similar on the protein level. Proteins that had very significant
clustering, such as KRAS and TP53, remain very significant when the tertiary
structure is incorporated. Proteins that were less significant, such as IDE and
AKT1, remain so as well.
iPAC NMC
Protein P-value P* P-value P*
KRAS 6.17 E-185 6.35 E-181 4.39 E-233 4.52 E-229
TP53 5.23 E-128 6.11 E-123 4.37 E-086 5.30 E-81
BRAF 3.73 E-130 1.01 E-126 3.84 E-130 1.04 E-126
PIK3CA 8.20 E-084 3.58 E-80 8.20 E-084 3.58 E-80
NRAS 5.38 E-026 6.46 E-24 8.26 E-029 9.91 E-27
HRAS 1.23 E-010 5.54 E-09 5.61 E-010 8.42 E-09
AKT1 1.18 E-005 7.08 E-05 2.47 E-005 7.41 E-05
IDE 2.20 E-005 6.60 E-05 1.56 E-003 4.67 E-03
Table 1: A comparison of the most significant iPAC and NMC p-values from the 8 proteins
that were picked up by both algorithms. P* is calculated as described in Section 2.6.
We note that 9 out of the 11 proteins that were found significant by iPAC
had their most significant cluster overlap a binding site, proton acceptor site
or kinase domain. For the remaining 2 proteins, the most significant cluster
for PIK3CA overlapped amino acid 1047 which has been shown to ease the
entrance of substrates and hence potentially increase the substrate turnover
rate, a typical oncogenic behavior (Mankoo et al., 2009). For a detailed per
protein description, please see “Relevant Sites” in the supplementary materials.
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Finally, we considered the performance of iPAC as compared to two popular
machine learning algorithms, PolyPhen-2 (Adzhubei et al., 2010) and CHASM
(Carter et al., 2009). First, a direct comparison must be considered in light of
the fact that these algorithms require a much more extensive set of informa-
tion than iPAC . Nevertheless, over 98% of the amino acids that occurred in
significant mutation clusters were also identified as significant (with a FDR of
≤ 20%) by Polyphen-2 and CHASM. For full details, please see “Performance
Comparison” in the supplementary materials.
3.1 iPAC finds novel proteins
As discussed Section 3, three new proteins were identified by iPAC that were
missed when tertiary structures are not accounted for. The EGFR protein, a
cell-surface receptor for epidermal growth factor family ligands (Herbst, 2004),
is perhaps the most well known and has been found in a wide array of cancers
such as lung (Scagliotti et al., 2004), anal (Walker et al., 2009) and glioblastoma
multiforme (Heimberger et al., 2005). Although seven EGFR structures were
identified by iPAC to contain significant clustering, we will concentrate on the
2GS7 structure (Zhang et al., 2006) as it showed the most significant clustering.
As seen in Table 2, three significant clusters were found with cluster 3 being
being a sub-cluster of cluster 1. Figure 5, shows the orientation of these clusters
in three dimensional space.
Cluster Start End Muts. in Cluster P-Value
1 751 858 4 1.35E-04
2 719 751 2 2.41E-03
3 790 858 2 2.82E-03
Table 2: The three most significant clusters found in EGFR for the 2GS7 structure.
Overall, all the statistically significant clusters found deal with lung cancer
pathology and an increase in kinase activity. The two mutations in cluster 2,
G719S and T751I are both found in lung cancer with the first mutation respon-
sible for strongly increased kinase activity (Yun et al., 2007; Tam et al., 2006;
Paez et al., 2004) and the second found in erlotinib responsive non small cell
lung cancer patients (NSCLC) (Peraldo-Neia et al., 2011; Tsao et al., 2005), re-
spectively. Cluster 3 contains two mutations, T790M and L858R, both of which
have been found in lung cancer and are known for increased kinase activity as
well (Yun et al., 2008, 2007; Tam et al., 2006; Paez et al., 2004). Finally, clus-
ter 1 is comprised of clusters 2 and 3, with an additional mutation S768I which
potentially shows a positive clinical response to Getfinib in NSCLC patients
(Masago et al., 2010). It is interesting to note that both clusters 1 and 2, that
are identified via statistical analysis, contain mutations that have been found to
benefit from pharmacological intervention. Had the tertiary structure of EGFR
not been taken into account, these clusters would not have been identified by
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Figure 5: The 2GS7 structure color coded by region: 1) cluster 1 - orange, 2) cluster 2 -
blue and 3) cluster 3 - yellow. The boundary α-carbon amino acids of 719, 751, 768, 790 and
858 are shown as purple spheres.
the NMC algorithm. When the protein is viewed linearly, the mutations occur
too far away from each other to result in statistically significant p-values.
3.2 iPAC finds additional clusters
One example where iPAC finds additional clusters is in the KRAS protein when
analyzing the 3GFT structure1 (Tong et al., 2009). KRAS, part of the RAS set
of of proteins which are involved in a large number of signaling cascades, is one of
the most studied cancer oncogenes with activating mutations in approximately
17-25% of all human cancers (Kranenburg, 2005). While both NMC and iPAC
identified many of the same clusters such as amino acids 12-13, 12-61 and 12-
146, iPAC identified several novel clusters as well, specifically amino acids 61-
117 and 117 -146. We note that both algorithms specifically identify a cluster
between residues 12 and 146, and given that we only have positional data for
167 residues, signifies that there is one large cluster that covers ≈ 80% of all the
available amino acids. However, combined with the two novel clusters identified
by iPAC , we are able to partition the protein into three distinct regions 1) 12-
61, 2) 61 - 117 and 3) 117-146 that cover 30%, 34% and 18% of the protein
respectively (see Figure 6).
1For this analysis, we included included mutational and positional data only on residues
1-167. No 3D positional information was available in the 3GFT structure on residues 168-
188, and these residues were removed before the analysis. Further, the structural information
has amino acid 61 as a histidine (isoform 2B for KRAS in the Uniprot Database) while the
COSMIC database has a glutamine in that position. However, as the substitution of one amino
acid in the structure for another would not have a significant affect on its spatial orientation
and as amino acid 61 has a large number of somatic mutations, it was kept in the analysis.
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Figure 6: The 3GFT structure color coded by region: amino acids 13-60 are blue, 62-116
are red and 118-145 are yellow. The boundary α-carbon amino acids of 12,61,117 and 146 are
shown as purple spheres.
We also ran NMC and iPAC on each region separately to consider how the
clustering results would be affected. As can be seen from Table 3, failure to
account for the tertiary protein structure resulted in region 3 no longer being
detected and region 1 losing significance by over ninety orders of magnitude.
P-value
Region NMC iPAC
1) 12-61 1.37E-11 3.36E-105
2) 61-117 - -
3) 117-146 - 3.35E-12
2&3) 61 - 146 - 3.31E-05
Table 3: P-value for each region when the region is considered independently. A “-”
signifies that the region was not found to be significant.
Further, while somatic mutations in region 12-61 have been found in many
cancers such as colorectal, lung, pancreatic and bladder (Sjblom et al., 2006;
Tam et al., 2006; Lee et al., 1995; Motojima et al., 1993; Nakano et al., 1984;
Santos et al., 1984), somatic mutations at amino acids 61, 117 and 146 have
primarily been found in lung and colorectal carcinomas. Even more specifi-
cally, mutations at amino acids 117 and 146 (K → N and A → T, respectively)
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deal mostly with colorectal cancer (Sjblom et al., 2006). Thus, by taking into
account the tertiary structure, the clusters identified by iPAC subdivide the
protein along pathological lines.
3.3 iPAC finds fewer clusters than NMC
Of the 215 structures found to contain significant clustering, 86 structures were
identified where iPAC found fewer structures than NMC. Three of these struc-
tures correspond to BRAF, 31 correspond to HRAS and 52 correspond to TP53.
Here, we consider structure 3TV4 (Wenglowsky et al., 2011) for the BRAF pro-
tein as it contains the most significant cluster found by both iPAC and NMC.
For this protein, it is well known that amino acid 600 is one of the most highly
mutated residues. In our dataset, 60 of the 76 total mutations that fulfilled the
requirements described in section 2.1 occurred on amino acid 600. As expected,
the most significant “cluster” is located solely on that amino acid, with an iPAC
p-value of 3.73×10−130 and an NMC p-value of 3.84×10−130. However, in total,
iPAC identifies 9 clusters for this structure while NMC identifies 19, with the
differences shown in Table 4.
Figure 7: The 3TV4 structure color coded by region: 1) Amino 464-600 are blue 2) Amino
Acids 601-671 are orange. The α-carbons of the mutated amino acids 464, 466, 469, 581, 596,
597, 601 and 671 are shown as purple spheres. Amino acid 600 is colored red.
While it is outside the scope of this paper to consider all the differences
between Tables 4a and 4b, we would like to point out that, contrary to iPAC ,
the NMC algorithm reports the two longest clusters: 1) 464 - 671 (p-value =
6.01 × 10−9 ) and 2) 469-671 (p-value = 2.38 × 10−8). After alignment of the
structure as described in Section 2.2, we only have structural information on
amino acids 448 - 723. Thus, the largest cluster detected by NMC covers ≈ 75%
of all the amino acids that we are considering. However, by taking into account
13
P-value
Start End # Muts. iPAC NMC
600 600 60 3.73 E-130 3.84 E-130
469 600 70 9.76 E-122 5.63 E-16
600 601 62 3.10 E-79 1.35 E-117
597 600 62 4.05 E-77 2.20 E-105
464 600 71 1.25 E-73 1.74 E-16
596 600 64 3.06 E-73 8.28 E-103
581 600 66 1.99 E-51 2.96 E-64
600 671 63 7.78 E-15 3.54 E-28
469 469 4 7.50 E-04 7.50 E-04
(a) Clusters found by both NMC and iPAC
Start End # Muts. NMC Pvalue
597 601 64 8.28 E-103
596 601 66 9.97 E-102
581 601 68 8.73 E-67
596 671 67 1.10 E-31
597 671 65 1.93 E-29
581 671 69 2.22 E-28
464 601 73 7.09 E-19
469 601 72 3.58 E-18
464 671 74 6.01 E-09
469 671 73 2.38 E-08
(b) Clusters dropped by iPAC
Table 4: The significant clusters found by both iPAC and NMC are shown in Table 4a.
The clusters that were not deemed significant by iPAC but were deemed significant by NMC
are shown in Table 4b.
the 3D structure of the protein, these ultra-long clusters are dropped and the
clusters where iPAC and NMC overlap show 2 distinct areas of the protein,
amino acids 464-600 and 600-671. As expected, as the majority of mutations
occur on amino acid 600, both NMC and iPAC declare that the “cluster” located
at amino acid 600 is highly significant.
Further, as described below, by considering only the clusters when tak-
ing into account the 3D structure (see Figure 7), the results again tend to
fall along pathological function. After applying the methodology described
in Section 2.1, the mutations that were found to be in significant clusters
included G464V, G466V, G469V, G469A, N581S, G596R, L597V, LV597R,
V600E, V600K, K601N and R671Q. As R671Q was found in only one sample
within the COSMIC database and does not have extensive literature, we will
not include it in further discussion. Taking into account the 3 most significant
clusters picked up by iPAC and NMC, we now consider the protein in 3 parts:
A) Residues 469 - 599, B) Residue 600 and C) Residue 601 (we have slightly
adjusted the clusters displayed in Table 4a to avoid overlap). The mutations
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listed that fall with region A, correspond primarily to lung and colorectal can-
cer (Gandhi et al., 2009; Pratilas et al., 2008; Greenman et al., 2007; Lee et al.,
2003; Davies et al., 2002; Naoki et al., 2002). Region B, which is comprised of
only amino acid 600 is by far the most common mutation with BRAF. This mu-
tation results in constitutive and elevated kinase activity and has been found
in a large range of cancers including colorectal carcinoma, ovarian serous car-
cinoma, metastatic melanoma and pilocytic astrocytoma. Further, supporting
the hypothesis that somatic clusters might provide pharmacological targets, it
has already been shown that suppression of this cluster in melanoma causes
tumor growth arrest and helps promote apoptosis (Andreu-Prez et al., 2011;
Greenman et al., 2007; Sjblom et al., 2006; Hingorani et al., 2003; Rajagopalan et al.,
2002; Davies et al., 2002). Finally, the K601N mutation in region C has been
found in multiple myeloma patients who also may benefit from BRAF inhibitors
(Chapman et al., 2011).
4 Conclusion
In this paper, we extended the existing methodology available to find somatic
mutation clustering by utilizing the information provided in the protein tertiary
structure. In doing so, we showed that we are able to find both new proteins
with clustering as well as new clusters in previously found proteins. We have
also shown that by taking into account 3D structure, we are able to remove
clusters that do not have biological meaning. The method is fast and robust,
with the vast majority of proteins analyzed within 5-10 minutes when executed
on a desktop with 8 GB of DDR3 RAM and an Intel i7 3600k processor running
at a frequency of 3.40 GHZ. Further, as the underlying calculation relies upon
the NMC algorithm, a preset fixed window size is not required which allows for
the detection of clusters of various lengths (Ye et al., 2010). We have also shown
that by employing a completely statistical methodology, we are able to identify
mutations that when may be suppressed via pharmacological intervention and
stop further tumor growth.
This methodology, while an improvement on the NMC method, still suffers
from some limitations. First, the mutation status of all the amino acids must
be determined although with the advent of high-throughput sequencing, this
will become less of an issue as time progresses. Also, both hypermutability of
genomic locations and unequal rates of mutagenesis might violate the assump-
tion that each amino acid has a uniform mutation probability. For instance, it
is well known that hypermutable positions for both somatic and germline muta-
tions exist. Insertions and deletions that are typically sequence dependent have
been removed from the analysis and only missense substitutions of single amino
acids have been kept in this study to help reduce such uniformity violations.
Similarly, CpG dinucleotides can have mutational frequency that is ten times
or more that of other dinucleotides (Sved and Bird, 1990). However, less than
13% of the mutations used to find clustering in Sections 3.1, 3.2, and 3.3 were
in CpG sites. Further, as described by Ye et al. (2010), tobacco smoking pref-
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erentially causes transversions in lung cancer while the mutational landscape
for colorectal cancer has more transitions (Hollstein et al., 1991). Nevertheless,
in the context of KRAS, the vast majority of mutations occur on amino acids
12, 13 and 61 for both lung and colorectal cancer. This suggests that while the
mutational spectrum may be different, it does not have a large effect on the
position of mutations and thus the uniformity assumption. As with previous
studies, while this analysis is influenced by nonrandom factors, it nonetheless
appears that selection of a cancer phenotype is the primary cause of clustering.
It should also be noted that while iPAC is designed to take tertiary structure
into account, it is only able to do so by appealing to the MDS methodology.
Future research is required in order to relax this restriction to potentially identify
additional clustering results. Finally, as shown in Section 3, iPAC finds fewer
clusters for a significant percentage of the structures analyzed. This reduction
in total clusters can come from two sources: the removal of some amino acids
due to lack of tertiary position information or that the cluster is no longer found
to be significant when 3D structure is taken into account. The first source, while
already rare will become even more so in the future as more detailed structural
information becomes available. As for the second source, when a cluster is
not identified under iPAC when compared to NMC, an overlapping or nearby
cluster is typically found (as shown in Tables 4a and 4b). For BRAF specifically,
there was a total of 3 structures where iPAC found fewer clusters than NMC.
Further, every “possibly” or “probably damaging” mutation, as categorized by
PolyPhen-2 (Adzhubei et al., 2010), was still represented in at least one cluster
in each structure. Thus, in the case of BRAF, none of the damaging mutations
identified by PolyPhen-2 were lost. For a more detailed analysis, please see
“Potential Driver Loss” in the supplementary materials. Ultimately, further
research is required to further reduce the possibility of losing driver mutations
while taking into account tertiary structure.
In conclusion, we present a novel approach to identifying mutation clus-
tering while taking into account protein tertiary structure. We further show
that by taking into account tertiary structure we are able to detect clusters
that would otherwise be missed. Next, we demonstrate that for some of the
clusters found, pharmacological intervention has already been successfully ap-
plied, further confirming the hypothesis that mutational clustering might point
to activating driver mutations. As additional protein structures continue to be
solved, iPAC would be able to rapidly perform a statistical analysis to identify
such potential mutations. Finally, as we gain a better understanding of the
tertiary structure of DNA, this method might also have applications to finding
mutational clustering on the DNA level.
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